Bevacizumab as a treatment option for choroidal neovascularisation due to large optic nerve drusen in a 14-year-old girl.

GMS ophthalmology cases Pub Date : 2020-08-06 eCollection Date: 2020-01-01 DOI:10.3205/oc000160
Nils Alexander Steinhorst, Martin Spitzer, Christos Skevas
{"title":"Bevacizumab as a treatment option for choroidal neovascularisation due to large optic nerve drusen in a 14-year-old girl.","authors":"Nils Alexander Steinhorst,&nbsp;Martin Spitzer,&nbsp;Christos Skevas","doi":"10.3205/oc000160","DOIUrl":null,"url":null,"abstract":"<p><p><b>Purpose:</b> To report the effects of a single intravitreous injection of bevacizumab for the treatment of secondary choroideal neovascularisation due to large optic disc drusen. <b>Methods:</b> A 14-year-old female patient with painless loss of vision in one eye presented with unusually large optic disc drusen and juxtapapillary choroidal neovascularisation with subretinal hemorrhage. She was treated with a single intravitreous injection of bevacizumab. <b>Results:</b> Visual acuity increased from 20/100 to 20/25 within 4 weeks after injection and remained at this level during the 12-month follow-up period. <b>Conclusions:</b> Bevacizumab is a possible primary treatment option for secondary choroidal neovascularisation due to large optic disc drusen in children as an alternative to other more invasive or complex procedures.</p>","PeriodicalId":73178,"journal":{"name":"GMS ophthalmology cases","volume":"10 ","pages":"Doc33"},"PeriodicalIF":0.0000,"publicationDate":"2020-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452948/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"GMS ophthalmology cases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3205/oc000160","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To report the effects of a single intravitreous injection of bevacizumab for the treatment of secondary choroideal neovascularisation due to large optic disc drusen. Methods: A 14-year-old female patient with painless loss of vision in one eye presented with unusually large optic disc drusen and juxtapapillary choroidal neovascularisation with subretinal hemorrhage. She was treated with a single intravitreous injection of bevacizumab. Results: Visual acuity increased from 20/100 to 20/25 within 4 weeks after injection and remained at this level during the 12-month follow-up period. Conclusions: Bevacizumab is a possible primary treatment option for secondary choroidal neovascularisation due to large optic disc drusen in children as an alternative to other more invasive or complex procedures.

Abstract Image

Abstract Image

贝伐单抗作为治疗14岁女孩视神经萎缩所致脉络膜新生血管的选择。
目的:报道单次玻璃体内注射贝伐单抗治疗视盘肥大引起的继发性脉络膜新生血管的效果。方法:1例14岁女性无痛性失明患者,以视盘异常肿大、乳头旁脉络膜新生血管形成伴视网膜下出血为主要表现。她接受了单次玻璃体内注射贝伐单抗的治疗。结果:注射后4周内视力由20/100提高到20/25,随访12个月视力维持在20/100水平。结论:贝伐单抗是儿童视盘过大致继发性脉络膜新生血管形成的主要治疗选择,可替代其他更具侵入性或更复杂的手术。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
审稿时长
6 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信